Press Release PDF

Axcelead, Inc. announces that the following executive appointments were made at the Annual General Meeting of Shareholders held on June 28, 2024 and the Board of Directors meeting held after the Annual General Meeting of Shareholders.

1. Directors (Effective June 28, 2024)

Name	New / Reappointment	New Position, etc.
Tomoyuki Fujisawa	Reappointment	Chairperson
Nobuhiro Todokoro	New	Representative Director
Yoshinori Ikeura	Reappointment	Board Director
Satoru Iino	Reappointment	Board Director
Junichi Kajimoto	New	Board Director
Seiji Toyama	Reappointment	External Board Director
Tadashi Takiguchi	Reappointment	External Board Director
Nobuhiko Yamada	Reappointment *1	Director (Full-time Audit Board Member)
Takuji Ikuta	Reappointment	Outside Director (Audit Committee Member)
Emi Kunitomo	Reappointment	Outside Director (Audit Committee Member)

*1  Nobuhiko Yamada, who was a Board Director, was reappointed as a member of the Audit Committee. Nobuhiko Yamada will be a full-time Audit Board Member.

*2  Hiroki Maekawa, Masamichi Sato, and Miho Fujisawa, who were directors, will retire from their posts as directors at the end of the Ordinary General Meeting of Shareholders on June 28, 2024 due to expiration of their terms of office, and will become executive officers. This is based on the Group’s policy to further strengthen corporate governance by separating management oversight and execution.

*3  Atsushi Matsumura, the former Chairperson, and Makoto Kojima, Director, who was a member of the Audit Committee, resigned due to expiration of their term of office at the end of the Ordinary General Meeting of Shareholders on June 28, 2024.

[Reason for the change in representative directors]

To further strengthen the management structure in accelerating the Group’s growth.

2. Executive Officer (effective July 1, 2024)

Name	New Position	former position
Nobuhiro Todokoro	Representative Director, President and CEO	Corporate Officer
Yoshinori Ikeura	Borad Director, Co-CEO and CTO	President and CEO
Hiroki Maekawa	Corporate Officer CFO	Board Director and Chief Financial Officer / Chief Administrative Officer (CFO/CAO)
Masamichi Sato	Corporate Officer CSO	Board Director and Chief Operating Officer（COO)
Miho Fujisawa	Corporate Officer (Impact Management Supervisor)	Corporate Officer Group HR
Yo Nakajima	Corporate Officer (Group DX Supervisor)	Corporate Officer, Group DX
Satoshi Takamatsu	Corporate Officer (CDMO business Supervisor)	Corporate Officer, Head of CDMO Business
Kengo Okada	Corporate Officer (Drug Discovery Support Business Supervisor)	Corporate Officer, Head of CRO Business

3. Profile of Nobuhiro Todokoro, new Representative Director, President and CEO

2023      Managing Director, Whiz Partners Inc. Resigned in conjunction with his appointment as President 　
　　　　and CEO of Axcelead, Inc.
2022      Representative Director, Senior Managing Executive Officer, Nitto Denko Corporation
2021      Director, Senior Managing Executive Officer, Nitto Denko Corporation
2019      Director, Managing Executive Officer, Nitto Denko Corporation
2017      Executive Officer, General Manager of Information Functional Materials Business Division, Nitto
　　　　Denko Corporation
　　　　Director, Senior Executive Officer, General Manager of Information Functional Materials Business
　　　　Division, Nitto Denko Corporation
2015      Executive Officer, General Manager of Information Functional Materials Division, Information
　　　　Functional Materials Business Unit, Nitto Denko Corporation
1989      Nitto Denko Corporation

【About Axcelead】

Axcelead represents a holding company as healthcare platformer which owns a group of companies which are developing a world-class healthcare platform for drug discovery. Axcelead DDP, Japan’s first integrated drug discovery CRO, functions as the core company of the Axcelead group that took over Takeda Pharmaceutical Company Limited’s drug discovery platform business in 2017. ARCALIS has become Japan’s only one-stop mRNA contract drug development and manufacturing organization (CDMO).

Axcelead also owns A-Digital, which develops a drug discovery digital platform to increase drug discovery efficacy by 100 times, and the American company, PassPort Technologies, Inc. in San Diego, California (“PassPort”). PassPort is a company that develops combination products of active pharmaceutical ingredients and medical devices based on next-generation transdermal drug delivery technology. Axcelead will promote the drug discovery ecosystem in Japan and will make various contributions to healthcare broadly and globally.

For more information on Axcelead, please visit the company’s website at https://www.axcelead-hd.com